These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20203453)

  • 1. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease.
    McCullough PA; Verrill TA
    Postgrad Med; 2010 Mar; 122(2):25-34. PubMed ID: 20203453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease and cardiovascular disease: a case presentation.
    McCarley PB; Salai PB
    Nephrol Nurs J; 2007; 34(2):187-98; quiz 199-200. PubMed ID: 17486949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micronutrients and cardiorenal disease: insights into novel assessments and treatment.
    McCullough PA
    Blood Purif; 2011; 31(1-3):177-85. PubMed ID: 21228587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
    Ravera M; Paoletti E
    Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial dysfunction and chronic kidney disease: treatment options.
    Wu-Wong JR
    Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality.
    McCullough PA; Li S; Jurkovitz CT; Stevens L; Collins AJ; Chen SC; Norris KC; McFarlane S; Johnson B; Shlipak MG; Obialo CI; Brown WW; Vassalotti J; Whaley-Connell AT; Brenner RM; Bakris GL;
    Am Heart J; 2008 Aug; 156(2):277-83. PubMed ID: 18657657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients.
    Curtis BM; Levin A; Parfrey PS
    Med Clin North Am; 2005 May; 89(3):511-23. PubMed ID: 15755465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing cardiovascular disease in patients with renal disease.
    Crook ED; Washington DO
    Ethn Dis; 2002; 12(4):S3-1-4. PubMed ID: 12477146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease.
    Marrs JC
    Am J Manag Care; 2011 Dec; 17 Suppl 15():S403-11. PubMed ID: 22214475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR
    Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease.
    McCullough PA; Lepor NE
    Rev Cardiovasc Med; 2005; 6 Suppl 3():S4-12. PubMed ID: 16340933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidemias in patients who have chronic kidney disease.
    Farbakhsh K; Kasiske BL
    Med Clin North Am; 2005 May; 89(3):689-99. PubMed ID: 15755473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
    Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy.
    Notaro LA; Usman MH; Burke JF; Siddiqui A; Superdock KR; Ezekowitz MD
    Cardiovasc Ther; 2009; 27(3):199-215. PubMed ID: 19689620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.